Market Impact of EMA decision on GBCAs

Written by Steve Holloway

Published: March 22, 2017

The recommendation by the European Medicines Agency (EMA) on 10 March that market authorisation for four linear gadolinium contrast agents (GBCAs) be suspended shocked the radiology community, but very little has been said about this decision’s effect on businesses.

Supply of the agents in question is significant business for Bayer HealthCare Pharmaceuticals (Magnevist), GE Healthcare (Omniscan), Bracco (MultiHance), and Guerbet (Optimark), and Europe’s one of their largest and most mature marketplaces. So, what will be the market repercussions?

Fight or flight? It’s not all black and white

The information offered with the EMA announcement provides a few clues about how the market will react. However, it’s clear that a swift reversal of the recommendation and soon-expected EMA suspension is unlikely.

This is the opening extract of Steve’s regular monthly market column for AuntMinnie Europe.  

To read the full article, please click here.

(Access to the article may require free membership to AuntMinnie Europe – it’s full of great content and insight so well worth signing up!)